• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Plastic surgery clinic targets former employees in copyright and TM suit
trademark-istock-508118711-timarbaev-
timarbaev / iStockphoto.com
11 January 2019MedTech

Plastic surgery clinic targets former employees in copyright and TM suit

A New York-based plastic surgery clinic has taken legal action against two former employees and a rival clinic for copyright infringement, trademark counterfeiting and dilution, and cybersquatting.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026   The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.
MedTech
Invisalign maker secures first China win against clear aligner rival
13 August 2026   Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.
MedTech
The UPC plugs another gap in its procedural rulebook
7 August 2026   A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

More features

White & Case life sciences co-leader moves firms
‘Busiest’ US district patent judge swaps bench for private practice
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Pinsents expands German patent practice with partner duo
Tempus AI bid to derail DNA patent case hits snag
Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026
Teva faces scrutiny over efforts to curb generic competition
FDA targets faster generic approvals in drive to slash drug prices

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin